Beta-cell renewal

Not protecting the beta cells you still have — making more. Adult human beta cells barely divide, which is why this is the hardest problem in diabetes and why every honest account separates preservation from regeneration.

Beta-cell growth brake reduces it.

The brake, with a genetic counterfactual. Verbatim: 'we find that analogs of the small molecule harmine function as a new class of human beta cell mitogenic compounds. We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target' (PMID 25751815). The counterfactual: 'silencing DYRK1A in human beta cells fully reproduces the harmine-induced proliferation' - the genetic knockdown reproduces the drug, so the target is confirmed, not inferred. Nothing on this blend inhibits DYRK1A. This edge exists to explain why beta-cell regeneration is hard, not to license a claim. PMID 25751815

Glucagon cells increases it.

The reservoir a person already owns. Verbatim: 'a cluster of cycling alpha cells, identified through single-cell human islets transcriptomics, may serve as a beta cell regenerative reservoir and may be readily transdifferentiated into functional human beta cells' (Cell Rep Med, S2666379124006037). The inference is forced by arithmetic: proliferation in vivo is 'modest (~0.2%-0.5%) and cannot explain the 300%-700% increase in beta cell mass', and 'despite the dramatic increase in human beta cell mass, there is NO accompanying increase in alpha cell mass'. transdifferentiation is inferred from the mass arithmetic and lineage markers, not from a lineage-tracing experiment in humans. PMID 40544428

Appetite & sugar hormone increases it.

10.1159/000374027 — Verbatim: 'DYRK1A inhibitors are able to drive human beta cell proliferation in vitro and in vivo, an effect that can be further augmented by combined treatment with a number of GLP-1RAs, or TGF-beta superfamily antagonists' - harmine plus exendin-4 raised human beta-cell mass 700% versus 300% for harmine alone. the GLP-1 contribution here is as an AUGMENTER of a DYRK1A inhibitor, not as a regenerative agent on its own. doi 10.1159/000374027

Pancreatic ducts increases it.

10.1371/journal.pone.0004734 — The second source of new beta cells. Verbatim (CIBERISCIII, Spain): 'han demostrado que las células beta se regeneran desde DOS Fuentes diferentes: a partir de la transformación de las células alfa en beta y también mediante LA FORMACIÓN DE NUEVAS CÉLULAS beta PRODUCTORAS DE Insulina EN LOS DUCTOS PANCREÁTICOS' — beta cells regenerate from two different sources: transformation of alpha cells into beta cells, and the formation of new insulin-producing beta cells in the pancreatic ducts. demonstrated in a type 1 mouse model under LIRAGLUTIDE, a GLP-1 receptor agonist selected by neural-network screening of 6,605 drugs. Nothing on this blend is A GLP-1 agonist at a regenerative dose. This edge explains a route; it does not license a claim. doi 10.1371/journal.pone.0004734

It increases Protects insulin cells.

New beta cells become beta-cell mass. Verbatim: harmine 'is able to induce beta cell proliferation, increase islet mass and improve glycemic control' across 'three different mouse and human islet in vivo-based models' (PMID 25751815). measured with transplanted human islets in IMMUNODEFICIENT mice - a system with NO autoimmunity. Regeneration in the presence of an ongoing type 1 attack is a different and unsolved problem. PMID 25751815

It increases Insulin production marker.

New beta cells make insulin, and C-peptide is how you would know. Harmine 'increases expression of key beta cell transcription factors (PDX1, NKX6.1, MAFA, MAFB, NeuroD1) and phenotypic markers (GLUT2, PCSK1, GLP-1R, SLC30A8/ZnT8)' - the new cells are functionally beta, not merely insulin-positive. C-peptide would be the human readout; no human trial of any regenerative agent has reported it.

Pancreas Regenerator (Islet Cell Restoration) →